Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni

Pilsen 323 00

0 studies enrolling now · 4 studies all time

What they study most

Leukemia, Lymphocytic, Chronic, B-Cell, Multiple Myeloma, Smoldering Multiple Myeloma

Studies at this site

• A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) — Running, not enrolling
• A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma — Completed
• A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy — Completed
• A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma — Completed